2018
Trends in C-Reactive Protein, D-Dimer, and Fibrinogen during Therapy for HIV-Associated Multidrug-Resistant Tuberculosis.
Cudahy PGT, Warren JL, Cohen T, Wilson D. Trends in C-Reactive Protein, D-Dimer, and Fibrinogen during Therapy for HIV-Associated Multidrug-Resistant Tuberculosis. American Journal Of Tropical Medicine And Hygiene 2018, 99: 1336-1341. PMID: 30226135, PMCID: PMC6221241, DOI: 10.4269/ajtmh.18-0322.Peer-Reviewed Original ResearchConceptsC-reactive proteinMulti-drug resistant tuberculosisD-dimerMedian C-reactive proteinSerum C-reactive proteinHigher baseline fibrinogenMDR-TB therapyHIV-positive adultsDrug-resistant tuberculosisHIV-positive participantsHigher CRP concentrationsEarly treatment modificationBaseline fibrinogenTreatment initiationResistant tuberculosisCRP concentrationsTreatment modificationTreatment outcomesTreatment responseHigh riskHigh mortalityNormal levelsOlder ageEarly responseFibrinogen
2014
How can mathematical models advance tuberculosis control in high HIV prevalence settings?
Houben RM, Dowdy DW, Vassall A, Cohen T, Nicol MP, Granich RM, Shea JE, Eckhoff P, Dye C, Kimerling ME, White RG, . How can mathematical models advance tuberculosis control in high HIV prevalence settings? The International Journal Of Tuberculosis And Lung Disease 2014, 18: 509-514. PMID: 24903784, PMCID: PMC4436821, DOI: 10.5588/ijtld.13.0773.Peer-Reviewed Original ResearchConceptsHigh HIV prevalence settingsHIV prevalence settingsTB-HIVTuberculosis controlPrevalence settingsHigh human immunodeficiency virus (HIV) prevalenceHuman immunodeficiency virus (HIV) prevalenceTB ModellingHealth policy makersDifficult diagnosisDisease progressionHigh riskHigh mortalityHealth systemNatural progressionVirus prevalencePublic healthProgressionMortalityPrevalenceSettingAnalysis ConsortiumDiagnosisExpert discussion